MANNKIND CORP (MNKD) Fundamental Analysis & Valuation

NASDAQ:MNKD • US56400P7069

Current stock price

2.47 USD
-0.05 (-1.98%)
At close:
2.4956 USD
+0.03 (+1.04%)
After Hours:

This MNKD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. MNKD Profitability Analysis

1.1 Basic Checks

  • In the past year MNKD was profitable.
  • MNKD had a positive operating cash flow in the past year.
  • In multiple years MNKD reported negative net income over the last 5 years.
  • In multiple years MNKD reported negative operating cash flow during the last 5 years.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • The Return On Assets of MNKD (0.85%) is better than 87.91% of its industry peers.
  • MNKD's Return On Invested Capital of 7.96% is amongst the best of the industry. MNKD outperforms 92.13% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for MNKD is significantly below the industry average of 18.89%.
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROIC 7.96%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100 -150

1.3 Margins

  • Looking at the Profit Margin, with a value of 1.92%, MNKD belongs to the top of the industry, outperforming 88.10% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 16.59%, MNKD belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
  • MNKD's Gross Margin of 77.80% is amongst the best of the industry. MNKD outperforms 84.26% of its industry peers.
  • MNKD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

3

2. MNKD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MNKD is creating some value.
  • MNKD has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MNKD has more shares outstanding
  • Compared to 1 year ago, MNKD has a worse debt to assets ratio.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -4.24, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of MNKD (-4.24) is comparable to the rest of the industry.
  • MNKD has a debt to FCF ratio of 44.51. This is a negative value and a sign of low solvency as MNKD would need 44.51 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 44.51, MNKD belongs to the top of the industry, outperforming 89.06% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Altman-Z -4.24
ROIC/WACC1
WACC7.94%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • MNKD has a Current Ratio of 1.70. This is a normal value and indicates that MNKD is financially healthy and should not expect problems in meeting its short term obligations.
  • MNKD's Current ratio of 1.70 is on the low side compared to the rest of the industry. MNKD is outperformed by 79.85% of its industry peers.
  • A Quick Ratio of 1.50 indicates that MNKD should not have too much problems paying its short term obligations.
  • MNKD's Quick ratio of 1.50 is on the low side compared to the rest of the industry. MNKD is outperformed by 81.19% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.5
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

6

3. MNKD Growth Analysis

3.1 Past

  • The earnings per share for MNKD have decreased strongly by -28.75% in the last year.
  • Looking at the last year, MNKD shows a very strong growth in Revenue. The Revenue has grown by 22.23%.
  • The Revenue has been growing by 39.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%

3.2 Future

  • The Earnings Per Share is expected to grow by 52.44% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 17.70% on average over the next years. This is quite good.
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue Next Year36.86%
Revenue Next 2Y23.74%
Revenue Next 3Y16.07%
Revenue Next 5Y17.7%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 -1 -1.5

5

4. MNKD Valuation Analysis

4.1 Price/Earnings Ratio

  • MNKD is valuated quite expensively with a Price/Earnings ratio of 41.17.
  • MNKD's Price/Earnings ratio is rather cheap when compared to the industry. MNKD is cheaper than 90.79% of the companies in the same industry.
  • MNKD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.23.
  • MNKD is valuated quite expensively with a Price/Forward Earnings ratio of 46.37.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 90.21% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.42. MNKD is valued rather expensively when compared to this.
Industry RankSector Rank
PE 41.17
Fwd PE 46.37
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MNKD is valued cheaper than 93.86% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MNKD is valued cheaply inside the industry as 92.13% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 55.59
EV/EBITDA 15.2
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • MNKD has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as MNKD's earnings are expected to grow with 65.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y91.27%
EPS Next 3Y65.59%

0

5. MNKD Dividend Analysis

5.1 Amount

  • No dividends for MNKD!.
Industry RankSector Rank
Dividend Yield 0%

MNKD Fundamentals: All Metrics, Ratios and Statistics

MANNKIND CORP

NASDAQ:MNKD (3/20/2026, 8:10:59 PM)

After market: 2.4956 +0.03 (+1.04%)

2.47

-0.05 (-1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners58.06%
Inst Owner Change3.51%
Ins Owners1.57%
Ins Owner Change2.58%
Market Cap761.01M
Revenue(TTM)348.97M
Net Income(TTM)6.70M
Analysts85.33
Price Target9.8 (296.76%)
Short Float %8.6%
Short Ratio4.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-116.48%
Min EPS beat(2)-439.47%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)-85.96%
Min EPS beat(4)-439.47%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-74.12%
EPS beat(12)5
Avg EPS beat(12)-38.6%
EPS beat(16)6
Avg EPS beat(16)-28.6%
Revenue beat(2)2
Avg Revenue beat(2)6.39%
Min Revenue beat(2)0.33%
Max Revenue beat(2)12.45%
Revenue beat(4)3
Avg Revenue beat(4)2.28%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)12.45%
Revenue beat(8)6
Avg Revenue beat(8)2.33%
Revenue beat(12)9
Avg Revenue beat(12)3.51%
Revenue beat(16)12
Avg Revenue beat(16)6.12%
PT rev (1m)0%
PT rev (3m)6.13%
EPS NQ rev (1m)-142.9%
EPS NQ rev (3m)-164.32%
EPS NY rev (1m)-38.97%
EPS NY rev (3m)-51.42%
Revenue NQ rev (1m)5.83%
Revenue NQ rev (3m)7.85%
Revenue NY rev (1m)9.02%
Revenue NY rev (3m)11.75%
Valuation
Industry RankSector Rank
PE 41.17
Fwd PE 46.37
P/S 2.18
P/FCF 55.59
P/OCF 41.69
P/B N/A
P/tB N/A
EV/EBITDA 15.2
EPS(TTM)0.06
EY2.43%
EPS(NY)0.05
Fwd EY2.16%
FCF(TTM)0.04
FCFY1.8%
OCF(TTM)0.06
OCFY2.4%
SpS1.13
BVpS-0.17
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROCE 9.32%
ROIC 7.96%
ROICexc 10.76%
ROICexgc 55.79%
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
FCFM 3.92%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
ROICexc(3y)28.62%
ROICexc(5y)N/A
ROICexgc(3y)44.91%
ROICexgc(5y)N/A
ROCE(3y)12.18%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Debt/EBITDA 8.33
Cap/Depr 37.17%
Cap/Sales 1.31%
Interest Coverage 3.93
Cash Conversion 26.02%
Profit Quality 204.41%
Current Ratio 1.7
Quick Ratio 1.5
Altman-Z -4.24
F-Score5
WACC7.94%
ROIC/WACC1
Cap/Depr(3y)368.18%
Cap/Depr(5y)300.07%
Cap/Sales(3y)8.68%
Cap/Sales(5y)9.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%
Revenue Next Year36.86%
Revenue Next 2Y23.74%
Revenue Next 3Y16.07%
Revenue Next 5Y17.7%
EBIT growth 1Y-18.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.06%
OCF growth 3YN/A
OCF growth 5YN/A

MANNKIND CORP / MNKD Fundamental Analysis FAQ

What is the fundamental rating for MNKD stock?

ChartMill assigns a fundamental rating of 5 / 10 to MNKD.


Can you provide the valuation status for MANNKIND CORP?

ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.


Can you provide the profitability details for MANNKIND CORP?

MANNKIND CORP (MNKD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of MANNKIND CORP (MNKD) stock?

The Price/Earnings (PE) ratio for MANNKIND CORP (MNKD) is 41.17 and the Price/Book (PB) ratio is -14.92.